Mild cognitive impairment: Emerging therapeutics

Annals of Pharmacotherapy

Volumn 34, Issue 10, 2000, Pages 1179-1188

  Sramek, J J ^a   Veroff, A E ^a   Cutler, N R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer disease; Antiinflammatory drugs; Antioxidants; Estrogen; Mild cognitive impairment

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CELECOXIB; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; INDOMETACIN; MONOAMINE OXIDASE INHIBITOR; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; ROFECOXIB; SELEGILINE; TACRINE;

AGED; AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTHRITIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFECT; DRUG INDUCED DISEASE; ESTROGEN THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROLOGIC DISEASE; OXIDATIVE STRESS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0033774533     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19394     Document Type: Review

References (96)

1. Mild cognitive impairment: Clinical characterization and outcome
2. Mild cognitive impairment raises Alzheimer risk
3. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
4. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment
5. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
6. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities
7. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease
8. A follow-up study of age-associated memory impairment: Neuropsychological predictors of dementia
9. The clinical dementia rating (CDR): Current version and scoring roles
10. Rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment
11. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
12. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls)
13. Neuropathological staging of Alzheimer-related changes
14. Hippocampal atrophy in normal aging: An association with recent memory impairment
15. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
16. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment
17. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease
18. Alzheimer's disease neuropathology
19. Correlation of dementia severity with plaque and tangle frequencies in midfrontal cortex in CER-AD cases with Alzheimer's disease
20. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and decline with disease progression
21. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease
22. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
23. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity
24. The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status
25. Education and the incidence of dementia in a large population-based study: The Rotterdam Study
26. Are sex and educational level independent predictors of dementia and Alzheimer's disease? Incidence data from the PAQUID project
27. Age, education, and changes in the Mini-Mental State Exam scores of older women: Findings from the nun study
28. Education and decline in cognitive performance: Compensatory but not protective
29. Does education level determine the course of cognitive decline?
30. Factors associated with inconsistent diagnosis of dementia between physicians and neuropsychologists
31. Metamemory and depression in cognitively impaired elders
32. Auditory even-related brain potentials in hyperthyroidism
33. Psychic trauma causing grossly reduced brain metabolism and cognitive deterioration
34. Prevalence of mild cognitive impairment in an elderly community sample
35. Documentation and evaluation of cognitive impairment in elderly primary care patients
36. The Diagnostic Utility of Savings Scores: Differentiating Alzheimer's and Huntington's disease with the logical memory and visual reproduction tests
37. Senile dementia of the Alzheimer type
38. Neuropathological changes of the nucleus accumbens in Huntington's chorea
39. Neuropsychological end-organ reponses: The Computerized Neuropsychological Test Battery
40. A new assessment tool for neuropsychopharmacologic research: The computerized neuropsychological test battery
41. Efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using Computerized Neuropsychological Test Battery (CNTB)
42. CSF cholinesterase inhibition is a more accurate measure of cognitive effects than drug concentrations or peripheral inhibition in Alzheimer patients receiving rivastigmine
43. Animal models of memory impairment
44. Characterization of perforant path lesions in rodent models of memory and attention
45. Alzheimer disease: Evidence for the selective loss of cholinergic neurons in the nucleus basalis
46. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease
47. A controlled trial of tacrine in Alzheimer's disease
48. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
49. SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats
50. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor; in patients with mild to moderately severe Alzheimer's disease
51. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
52. Reminyl approved in second market
53. The pharmacology of galanthamine and its analogs
54. A 5-month, randomized, placebo-controlled trial of galantamine in AD
55. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group
56. Recent developments in the drug treatment of Alzheimer's disease
57. Potential applications for monoamine oxidase B inhibitors
58. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
59. Vitamin E protects nerve cells from amyloid-beta protein toxicity
60. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged
61. Utilization of vitamin E
62. Dissimilar protection of tocopherol isomers against membrane hydrolysis by phospholipase A2
63. Superior cognitive functioning in later life
64. Plasma antioxidants and cognitive performance in middle-aged and older adults: Results of the Austrian Stroke Prevention Study
65. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies
66. Anti-inflammatory drugs and Alzheimer's disease
67. Risk of Alzheimer's disease and duration of NSAID use
68. Human cyclooxygenase-2 cDNA
69. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
70. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
71. Estradiol and progesterone relates neuronal structure and synaptic connectivity in adult as well as developing brain
72. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood
73. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain
74. An evaluation of psychological effects of sex hormone administration in aged women: Results after six months
75. Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidant activities: 17 Alpha-substituted analogs of delta 9(11)-dehydro 17 beta-estradiol
76. 17 Beta-estradiol enhances the outgrowth and survival of neocortical neurons in culture
77. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro
78. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons
79. Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease
80. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women
81. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
82. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double blind study
83. In vivo effects by estrone sulfate on the central nervous system-senile dementia: Alzheimer's type
84. Educating patients about the benefits and drawbacks of hormone replacement therapy
85. Influence of cell culture conditions on the protective effects of antioxidants against beta-amyloid toxicity: Studies with lazaroids
86. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction
87. The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons
88. Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal fombrain cholinergic neurons in the rat
89. Highly selective effects of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 on intact and injured basal forebrain magnocellular neurons
90. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
91. Pharmacokinetics of propentofylline and the quantitation of its metabolite hydroxypropentofylline in human volunteers
92. A double-blind, placebo controlled study of ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment
93. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000
94. Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains
95. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse
96. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. North American EGb Study Group